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Abstract
Introduction: to evaluate, over 24 months of prospective follow-up, the dosage and costs of lanreotide AUTOGEL 120 mg (ATG120) 
administered as part of routine acromegaly care in Poland.
Material and methods: A multicentre, non-interventional, observational prospective study on resource utilisation in Polish acromegalic 
patients treated with ATG120 at 4-week or extended (> 4 weeks) dosing interval. The study population consisted of adult acromegalic 
patients treated for at least 3 injections of ATG120. The endpoints were: percentage of patients treated with ATG120 at an extended dos-
ing interval (> 4 weeks), mean time between injections, and the cost of ATG120 during a 24-month prospective observation. Costs were 
calculated in PLN from the public health-care payer and patient perspective for the year 2014.
Results: 143 patients were enrolled in, and 132 completed (70% women, 81% macroadenoma, 75% previous surgery) the analysis. During 
two years, changes in the treatment pattern were reported in 41 patients: 17% of them had increased injection interval and 10% switched 
to octreotide LAR and then returned to ATG120. Sixty-three patients (48%) received ATG120 at an extended dosing interval. ATG120 was 
predominantly administered in an out-patient setting (84%) by a health care professional (97%).
Conclusions: The results demonstrated that extended dosing interval of ATG120 is used in a substantial proportion of patients in routine 
clinical practice in Poland. Such findings support the potential for ATG120 in reducing treatment burden in the real-world clinical envi-
ronment. (Endokrynol Pol 2015; 66 (2): 142–148)
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Streszczenie
Wstęp: Ocena schematu dawkowania i kosztu lanreotydu Autogel 120 mg (ATG120) stosowanego w leczeniu akromegalii w Polsce.
Materiał i metody: Wieloośrodkowe, nieinterwencyjne, obserwacyjne badanie prospektywne oceniające zużycie zasobów ochrony zdrowia 
w populacji polskich pacjentów z akromegalią leczonych ATG120 z zastosowaniem 4-tygodniowego lub wydłużonego (> 4 tygodni) od-
stępu między dawkami leku. Do badania włączani byli dorośli pacjenci, którzy otrzymali co najmniej 3 dawki ATG120. Horyzont czasowy 
badania wynosił 24 miesięcy. Koszt leku obliczono z perspektywy płatnika publicznego i pacjenta w 2014 roku. 
Wyniki: Do badania włączono 143 pacjentów, 132 z nich ukończyło badanie (70% kobiet, u 81% makrogruczolak, 75% było wcześniej 
leczonych chirurgicznie). W czasie 2 lat zmiany schematu leczenia dokonano u 41 chorych, u 17% z nich wydłużono odstęp między 
dawkami, u 10% - zmieniono lek na oktreotyd LAR a potem ponownie zastosowano ATG120. U 63 pacjentów (48%) odstęp pomiędzy 
dawkami ATG120 wynosił > 4 tygodnie. ATG120 był przeważnie podawany ambulatoryjnie (84%) przez fachowy personel medyczny (97%). 
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Wnioski: Badanie wykazało, że w codziennej praktyce klinicznej u znaczącego odsetka pacjentów odstęp czasowy pomiędzy kolejnymi 
dawkami ATG120 jest dłuższy niż 4 tygodnie. Wynik ten potwierdza tezę, że dzięki stosowaniu ATG120 można obniżyć koszty leczenia 
akromegalii. (Endokrynol Pol 2015; 66 (2): 142–148)
Słowa kluczowe: akromegalia; lanreotyd Autogel; badanie kliniczne; koszt leczenia
The study was founded by Ipsen Poland.
Introduction
Lanreotide, one of two commercially available so-
matostatin receptor ligands (SRLs), is an established 
treatment for patients with acromegaly following 
unsuccessful pituitary surgery, in preparation for 
surgical treatment, and as a long-term therapy if sur-
gical treatment cannot be used [1]. A recent European 
study, PRIMARYS, designed to assess if ATG120 used 
as first-line therapy in patients with macroadenoma 
could reduce tumour volume, confirmed that in such 
therapy ATG120 not only improved symptoms and 
attenuated or normalised growth hormone (GH) and 
insulin-like growth factor 1 (IGF-1) hypersecretion, but 
also reduced tumour volume and improved quality of 
life [2]. The results showed a clinically relevant effect 
as expressed by the 63% of patients with a 20% or more 
tumour volume reduction [2].
Both SRL agents, lanreotide and octreotide, have 
been approved as depot formulations and are admin-
istered monthly, with an approved extension of a 6- to 
8-week injection interval possible for lanreotide [1]. 
The possibility of extending dosing intervals of drugs 
administered in injections may positively influence pa-
tients’ preference to treatment, compliance, and quality 
of life [1]. Studies have been conducted to investigate 
the efficacy and acceptability of extending the dosing 
interval beyond monthly [3, 4]. One study, conducted 
in Germany, enrolled patients who were previously 
treated with octreotide LAR doses of 10 mg, 20 mg, 
and 30 mg monthly and then switched to lanreotide 
AUTOGEL 120 mg (ATG120) at intervals of every 56, 
42, and 28 days, respectively [3], and the other was an 
international study enrolling patients well controlled 
on octreotide 10 or 20 mg (LEAD study) [4]. The results 
demonstrated for both studies that extended dosing is 
effective at achieving biochemical control with at least 
similar rates of control in patients who responded to the 
somatostatin analogues. Investigators judged the injec-
tions with lanreotide to be easier than using octreotide 
LAR, and patients preferred receiving injections less 
frequently. A recent study evaluating the efficacy and 
safety of extended dosing intervals with ATG120 in 
patients with acromegaly previously controlled with 
conventional doses of octreotide LAR every four weeks 
demonstrated that extended dosing intervals were 
associated with patient preference over octreotide [5].
So far, limited data have been published concerning 
dosing patterns and the cost of somatostatin analogues 
used for treatment of acromegalic patients in routine 
clinical practice [5, 6]. Findings that in a one-year time 
horizon approximately 50% of patients could be treated 
with dose intervals of longer than 28 days document the 
potential of ATG 120 to reduce treatment burden [5, 6]. 
The aim of this study was to evaluate, over 
24 months of prospective follow-up, the dosage and 
costs of lanreotide AUTOGEL 120 mg administered as 
part of routine acromegaly care in Poland. In this type 
of study the decision to prescribe the given medical 
product, treatment monitoring, dose adjustment, and 
all other medical decisions were made at the responsible 
physician’s discretion, according to the routine practice 
at the clinical site.
Material and methods
Lanro-Study was a national, multicentre, non-inter-
ventional, observational, prospective study conducted 
in accordance with the Declaration of Helsinki [7] and 
the International Ethical Guidelines for Epidemiological 
Studies, CIOMS, Feb 2008 [8]. This study also followed 
the recommendations of the International Epidemio-
logical Association Guidelines for Proper Conduct in 
Epidemiologic Research (GEP) — Nov 2007 [9], and 
the International Society for Pharmacoepidemiology 
(ISPE) Good Pharmacoepidemiological Practices (GPP) 
Guidelines, April 2007 [10]. All patients gave written 
informed consent before entering the study.
Patients were included in the study during routine 
out-patient visits. All sites that treat acromegaly patients 
meeting the study inclusion criteria were selected and 
contracted. Site selection was based on the ability to col-
lect the data in electronic format, motivation to partici-
pate, and fulfilment of all requirements of the protocol. 
Eligible patients were adults (≥ 18 years of age) with 
symptomatic acromegaly treated with ATG120 in rou-
tine practice for at least three months before inclusion. 
The decision to prescribe ATG120 was made prior to 
and independently of the decision to enrol the subject 
in this non-interventional study. Patients were excluded 
if they actively participated in any clinical study. 
Relevant data collected prospectively during 
24-months were captured on an electronic Case Re-
port Form (eCRF). The following data were gathered: 
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baseline patient characteristics (demographic infor-
mation, clinical assessment, relevant medical history, 
prior therapies) and data of current treatment. The 
primary objective was to evaluate over the 24-month 
prospective follow-up - in everyday clinical practice — 
resource utilisation and effectiveness of the treatment of 
acromegalic patients in Poland with ATG120, including 
extended injection intervals. 
The measured endpoints were: percentage of 
patients treated with ATG120 at an extended dosing 
interval (> 4 weeks), mean time between injections, 
and cost of ATG120 during the 24-month prospective 
observation.
Cost evaluation was performed from the perspec-
tive of the public payer, e.g. National Health Fund, 
and patients in 2014 (1 PLN = 0.25 EURO). Costs were 
assessed using a micro-costing approach, applying unit 
cost multipliers to the quantity of each type of resource 
consumed. Given the exploratory nature of the study, 
no formal statistical analysis was performed. 
Results
Characteristics of the population
A total of 151 patients, suffering from acromegaly 
for at least 1 year, were screened and 143 enrolled in 
35 centres across Poland between 29 Oct 2010 and 
31 March 2012. Of those, 11 patients were excluded 
from the analysis: 2 patients because of missing follow-
up visits and 9 patients because they did not complete 
the treatment period (24 months); thus there were 
132 patients in the completers group included into 
analysis (Table I). The baseline demographic character-
istics of the population included into analysis (n = 132) 
are summarised in Table II. At the time of inclusion 54% 
of patients with GH data (n = 101) achieved biochemi-
cal control of their disease, defined as GH ≤ 2.5 ng/mL. 
The most commonly reported symptoms of the disease 
were headache (84% of patients) and arthralgia (82% 
of patients), predominantly mild/moderate. Excessive 
sweating, easy fatigue, swelling of the area around 
joints, and wheezing were reported in 76%, 67%, 55%, 
and 69% of patients, respectively (Table III). In 13–15% 
of patients fatigue, arthralgia, and hoarseness were of 
high intensity.
Treatment history
With regard to previous acromegaly treatment, 
99 patients (75%) had undergone pituitary surgery. 
Twenty-three patients (17.4%) had received pituitary 
radiotherapy (Table IV). The mean time since surgery/
radiotherapy was 7.7/8.1 years, respectively. Differ-
ent combined treatment (somatostatin analogue + 
cabergoline or bromocriptine, or pegvisomant) was 
Table I. Duration of time for which the population was 
followed (n = 143)
Tabela I. Czas obserwacji (tygodnie) populacji pacjentów 
włączonych do badania (n = 143)
Time (weeks) No. of patients
104 132
122 1
98 1
97 1
78 1
76 1
75 1
68 1
59 1
52 1
0 2
Table II. Baseline characteristics of population included into 
analysis (n = 132)
Tabela II. Charakterystyka pacjentów włączonych do analizy 
(n = 132)
Variable Population 
Age: mean (SD) (years) 51.7 (14.3)
Weight: mean (SD) [kg] 82.8 (17.7)
BMI: mean (SD) [kg/m2] 29.4 (5.4)
Gender
Male: n (%) 39 (29.6) 
Female: n (%) 93 (70.5) 
Tumour size
Macroadenoma (≥ 10 mm in diameter): n (%) 108 (81.8)
Microadenoma (< 10 mm in diameter): n (%) 18 (13.6)
Not known: n (%) 6 (4.6)
Tumour diameter: mean (SD) [mm] 19.2 (11.2)
Diabetes mellitus, n (%) 40 (42.1)
Hypertension, n (%) 78 (82.1)
Cholelithiasis, n (%) 26 (27.4)
Table III. Acromegaly-related symptoms of the population 
included into the analysis (n = 132)
Tabela III. Objawy kliniczne akromegalii w populacji 
pacjentów włączonych do analizy (n = 132)
Symptom % of population 
Headache 84
Arthralgia 82
Sweating 76
Fatigue 67
Swelling of joint areas 55
Wheezing 69
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used in 15 patients (11.4%). As additional treatment, 
6 patients (4.5%) received bromocriptine, 8 patients 
(6.1%) — cabergoline and 1 (0.8%) — pegvisomant 
(Table IV). Almost 43% of patients were treated due 
to diabetes. Due to concomitant pituitary insuffi-
ciency, 52 patients (39.4%) were using levothyroxine, 
43 patients (32.6%) — hydrocortisone, 4 patients 
(3.0%) — desmopressin, and 28 patients (21.2%) — 
sex hormones (Table V). 
Treatment with lanreotide ATG120 during the 
24-month follow-up
During the 24-month prospective phase, 63 patients 
(48%) received ATG120 at an extended dosing interval 
(> 4 weeks), predominantly every 5 weeks (n = 28) or 
every 6 weeks (n = 19) (Table VI). The mean/median 
number of days between injections during 24 months 
was 35.1 (SD 8.2)/31. The dosing intervals set at the 
beginning of the study remained the same for 91 pa-
tients (69.6%) until the end of the study; ATG120 was 
administered every 4, 5, 6, 7, 8, and 9 weeks in 67%, 14%, 
10%, 2%, 5%, and 1% of patients, respectively. Changes 
in dosing regimen of ATG120 in clinical practice were 
reported in 41 patients (30.4%): for 7 subjects the in-
terval was increased, for 12 subjects the interval was 
shortened, for 18 patients the interval was alternately 
extended or shortened, and in 4 patients the treatment 
was switched: from ATG120 every 4 weeks to octreotide 
LAR 30 mg every 4 weeks and then to ATG120 every 
4 weeks (1 patient), from ATG120 every 5 weeks to oc-
treotide LAR 30 mg every 4 weeks and then to ATG120 
every 4 weeks (1 patient), from ATG120 every 4 weeks 
to octreotide LAR 30 mg every 4 weeks (1 patient), and 
from ATG120 every 4 weeks to octreotide LAR 20 mg 
every 4 weeks, then to octreotide LAR 30 mg every 
4 weeks and then to ATG 120 every 4 weeks (1 patient). 
ATG120 was predominantly administered in an 
outpatient setting (84% of injections) by a health care 
professional (97% of injections): a nurse (80% of injec-
tions) or physician (17% of injections) (Table VI). The 
number of unsupervised home injections was only 
76 (2.6% of the total number of injections). The mean/ 
/median time needed for preparation and adminis-
tration of ATG120 was 4.1 (SD 2.5)/4 minutes and 1.6 
(SD 1.4)/1 minutes, respectively; mean/median product 
wastage was 0.2 (SD 0.7)/0 mg. 
The cost of ATG120 calculated based on reim-
bursement status and retail price of the drug being 
in force from 1 November 2014 [11] was 4066.1 PLN/
month/1016.5 EURO (the amount covered by the public 
payer and paid by patient was 4062.5 PLN/1015.6 EURO 
and 3.6 PLN/0.9 EURO, respectively) (Table VII). This 
monthly cost is lower than the retail price per pack — 
4770.5 PLN/1192.6 EURO because of the possibility of 
extending dosing intervals of ATG120 in a substantial 
proportion of patients. 
Table IV. Treatment history at baseline in the population 
included into the analysis (n = 132)
Tabela IV. Leczenie stosowane w przeszłości u pacjentów 
włączonych do analizy (n = 132)
Variable Population
Pituitary surgery, n (%) 99 (75)
Time span since surgery: mean (SD) (years) 7.7 (6.7)
Radiotherapy, n (%) 23 (17.4)
Time span since radiotherapy: mean (SD) (years) 8.1 (6.5)
Bromocriptine, n (%) 6 (4.5)
Cabergoline, n (%) 8 (6.1)
Pegvisomant, n (%) 1 (0.8)
Table V. Concomitant treatments in the population included 
into the analysis (n = 132)
Tabela V. Leki dodatkowe stosowane w populacji pacjentów 
włączonych do analizy (n = 132)
Antidiabetic drugs n (%) 41 (42.3)
Oestrogens n (%) 18 (29.0)
Androgens n (%) 10 (16.1)
Hydrocortisone n (%) 43 (69.4)
Levothyroxine n (%) 52 (83.9)
Desmopressin n (%) 4 (6.5)
Table VI. Administration of ATG120 in 24-month time frame (setting, person administering ATG120)
Tabela VI. Warunki podawania ATG 120 w ciągu 24 miesięcy obserwacji (miejsce i osoba podająca lek)
Physician Person administering ATG120 Total
Care-giver Patient Nurse
Setting of 
administration
House – 48 28 30 106
Outpatient setting 430 9 1 2053 2493
Inpatient setting 63 3 1 289 356
Total 493 60 30 2372 2955
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Discussion
This real-life, observational study investigated dosage 
pattern and cost of ATG120 in the population of Polish 
patients with active acromegaly. The results showed 
that during two years 48% of patients were treated with 
a dose interval longer than 28 days. Approximately one 
third of patients required dosing adjustment, while in 
15% of them it was possible to increase the injection 
interval. ATG120 was predominantly administered in 
an outpatient setting by a health care professional. The 
results obtained during two years were consistent with 
those described in interim analysis with follow-up of 
one year [6]. This analysis revealed that 50% of patients 
received ATG120 at an extended dosing interval, and 
the mean number of days between injections was 35.6 
(SD 8.4). ATG120 was predominantly administered in 
an outpatient setting (77%) by a health care professional 
(94%) [6]. 
When interpreting the results of this study it is 
important to note the three following assets: First, the 
results have been obtained from a prospective study. 
These studies are considered to yield the most reliable 
real-world economic data that can contribute to the 
evidence base needed for coverage and payment deci-
sions [12]. Second, the time horizon of Lanro-Study was 
two years, and a high proportion of patients (92.3% of 
enrolled population) were followed-up, thus the results 
can be presumed reliable. Third, the study population, 
from 35 centres in different Polish regions, represents 
a wide cross-section of acromegalic patients in our 
country. About 80% of patients with a documented 
tumour size had a macroadenoma at diagnosis indicat-
ing that the analysed cohort was representative for the 
disease [13–23]. In the current analysis the prevalence of 
acromegaly in women is higher than in other registries 
[13–23], but the female predominance is in accordance 
with literature.
The percentage of patients treated previously with 
surgery is in the range of that reported from the Span-
ish and German registry (81% and 89%, respectively) 
[14,21], but higher than those reported from the Belgian 
cohort (68%) [16] or the UK National Acromegaly Reg-
ister (68.7%) [20]. In the present cohort, irradiation had 
been applied in 17% of cases. This is less than the num-
bers in the Belgian register (34%) [16] and about half of 
those published from the UK or Spain (48% and 45%, 
respectively) [13, 14]. A very recent publication from the 
Spanish Acromegaly Registry, however, documented a 
decline in the use of radiotherapy to 11.9% in patients 
diagnosed after 2000 [19]. 
Very limited data have been published concerning 
the dosing of SRLs in routine clinical practice [20, 21, 
23]. The UK Acromegaly Register collected routine bio-
chemical and clinical data on patients with acromegaly 
from 31 UK centres with GH data covering more than 
30 years [20]. In terms of medical treatment for acro-
megaly, 1549 patients (60.2%) had received some sort of 
medical therapy, and 40.6% had received SRLs (34.9% 
as monotherapy).
Doses of lanreotide ATG and octreotide LAR were 
examined in cases where this information had been 
entered in the database. There were 437 courses of 
octreotide LAR and 161 courses of lanreotide ATG. The 
mean/median dose for octreotide LAR was 22 mg/20 mg 
per month. Lanreotide ATG was given at the dose of 
30 mg (2%), 60 mg (35%), 90 mg (29%), 120 mg (34%), 
and 150 mg (1%). These data represent the dosages of 
each injection (typically monthly), but the data on the 
frequency of injection were recorded inconsistently in 
the original database and therefore were not analysed 
in the publication. Assuming that the doses presented 
above were per month, the mean/median dose of lan-
reotide ATG in the UK population was 89 mg/90 mg per 
month. Retrospective data analysis from 1344 patients 
followed in 42 centres of the German Acromegaly 
Register showed that in patients who were controlled 
by drug monotherapy, the median dose for octreotide 
LAR was 20 mg every 28 days (n = 182), and for lan-
reotide ATG 60 mg every 4 weeks (n = 27) [21]. The 
Table VII. Dosing regimen and cost of ATG120 during 24-month observation (n = 132)
Tabela VII. Schemat dawkowania i koszt ATG 120 w ciągu 24 miesięcy obserwacji (n = 132)
Dose Interval (weeks) N. of patients Cost/PLN/month*
Public payer + patient Public payer Patient
Lanreotide Autogel 120 mg
4
5
6
7
8
9
69
28
19
7
8
1
132 4066.13 4062.49 3.64 
*the cost of ATG120 was calculated based on reimbursement status and retail price of ATG120 being in force from 1 November 2014 [11]
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median doses for uncontrolled patients treated by drug 
monotherapy were, for octreotide LAR 30 mg every 
28 days (n = 78), and for lanreotide ATG 90 mg every 
28 days (n = 10) [21]. There were no differences in doses 
between patients with a long-standing (> 2 years) or 
a more recent (<= 2 years) diagnosis of acromegaly [21]. 
In the Somatuline Depot for Acromegaly (SODA) study 
carried out in the US, lanreotide ATG dose information 
was available for 146 patients at 12 months [23]. The 
majority of patients were taking lanreotide ATG 90 mg. 
Almost all patients (95%) received lanreotide ATG injec-
tions every 28 days, and one was receiving 120 mg at 
the extended dosing interval of every 42 days or longer. 
In total, 42 (29%) had dose adjustments in the first year 
of the study. The proportion of patients taking 90 mg 
decreased in the first year (from 57% to 43%), while the 
proportion taking 120 mg increased (from 27% to 43%), 
representing a general trend towards dose increase: 
mean/median dose at enrolment and after 12 months 
was 93.3 mg/90 mg and 98.7 mg/90 mg, respectively. 
The majority of patients (89%) received injections every 
28 days after 12 months of treatment [23]. In conclusion, 
the UK, German, and US real-life data revealed that the 
mean dose of lanreotide ATG per month was lower than 
120 mg, which is consistent with results of Lanro-Study, 
showing that 48% of patients could be treated with 
a dose of 120 mg given at an extended dosing interval.
Only the SODA study provided information on the 
aspects of drug administration [23]. Lanreotide ATG 
has the unique formulation of a prefilled self-injectable 
device, which offers a quick method of administration 
and allows for self- or partner-administration in the 
home or clinical setting. The proportion of patients in 
this study receiving injections from health professional 
(58/166; 35 %) was much lower than those reported 
from Lanro-Study. In the US study 16 % of patients self-
injected lanreotide, and the remaining 50% were evenly 
split between those who had injections administered 
by their partner and those who used a combination of 
methods [23]. In Polish routine practice the proportion 
of unsupervised home injections was 2.6%. The SODA 
study demonstrated that administration of lanreotide 
ATG at home by oneself or partner provides similar 
biochemical control to injections administered in the 
healthcare provider’s office, with similar tolerability 
and greater convenience. Such findings support the 
potential for lanreotide ATG to reduce treatment bur-
den in the real-world clinical environment and indicate 
that in the future unsupervised home injections might 
also be a viable alternative to healthcare professional 
injections for Polish patients.
The recently finished LEAD study evaluated the ef-
ficacy and safety of ATG120 extended dosing intervals 
in 124 patients from 14 countries previously controlled 
with conventional doses of octreotide LAR (10 or 20 mg 
every 4 weeks) [4]. At week 48, three-quarters of patients 
maintained IGF-1 control after switching to ATG120 
every 6 to 8 weeks. The benefits of ATG120, including 
the patients’ preference of this drug in extended dosing 
intervals, were achieved without safety or tolerability 
issues [4].
In conclusion, the Lanro-Study 2-year observation 
of a representative group of patients suffering from 
acromegaly indicates that ATG120 is economically pref-
erable due to its extended dosing interval used in almost 
half of patients. The subcutaneous, convenient method 
of administration via a prefilled syringe represents an 
additional benefit of this drug.
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